EuroBiotech: More Articles of Note

TiGenix priced its Nasdaq IPO, both the U.K.'s ABPI and Europe's EFPIA gained new leaders, while Ipsen lost its CSO.

> Ipsen has said that Claude Bertrand will step down as EVP, R&D and CSO with Alexandre Lebeaut to lead its research and development division in the interim. Capital story

> AstraZeneca’s U.K. head Lisa Anson has been elected as the next president of the Association of the British Pharmaceutical Industry (ABPI), the main pharma R&D trade group in Britain, starting in April. Release

> The European trade group for pharma R&D is also going through changes at the top, as EFPIA announces its long-term director-general Richard Bergström is to leave. EFPIA said it has appointed Eric Cornut as its interim director general. Statement

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Belgium biotech TiGenix has raised $35.65 million gross under its Nasdaq IPO, representing 46 million ordinary shares, at a price to the public of $15.50—a 14% discount on its shares. The company, which works on injectable stem cell therapies for perianal fistulas, plans to list on the Nasdaq under the symbol $TIG. Release

Suggested Articles

Inotrem and Roche’s diagnostics division have upgraded their years-long collaboration on a plasma test for septic shock, with a new worldwide deal.

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.